Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMN010
MIFTS: 62

Hemangioma

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hemangioma

About this section

MalaCards integrated aliases for Hemangioma:

Name: Hemangioma 12 74 29 54 6 44 15 17 71
Hemangiomas 15

Classifications:

MalaCards categories:
Global: Cancer diseases Fetal diseases Rare diseases Genetic diseases
Anatomical: Cardiovascular diseases Blood diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:255
ICD9CM 34 228.00
MeSH 44 D006391
NCIt 50 C3085
SNOMED-CT 67 154625006
ICD10 32 D18.0
UMLS 71 C0018916
Sources

Summaries for Hemangioma

About this section
Disease Ontology : 12 A cardiovascular organ benign neoplasm that has material basis in endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood.

MalaCards based summary : Hemangioma, also known as hemangiomas, is related to cavernous hemangioma and hemangioma, capillary infantile. An important gene associated with Hemangioma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Sufentanil and parecoxib have been mentioned in the context of this disorder. Affiliated tissues include Heart, endothelial and skin, and related phenotypes are shRNA abundance <= 50% and Decreased sensitivity to paclitaxel

Wikipedia : 74 A hemangioma or haemangioma is a usually benign vascular tumor derived from blood vessel cell types. The... more...

Sources

Related Diseases for Hemangioma

About this section

Diseases in the Hemangioma family:

Malignant Hemangioma Acquired Hemangioma
Familial Hemangioma Congenital Hemangioma

Diseases related to Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1299)
# Related Disease Score Top Affiliating Genes
1 cavernous hemangioma 33.2 PECAM1 NKX2-1 KRIT1 KDR FGF2
2 hemangioma, capillary infantile 33.1 MYH9 KDR FLT4 ANTXR1
3 cerebral cavernous malformations 32.9 TEK PTEN PECAM1 KRIT1 KDR
4 pyogenic granuloma 32.8 TEK KRAS GNA14
5 arteriovenous malformation 32.7 VEGFA TEK PTEN KRAS
6 intramuscular hemangioma 32.5 TEK PROX1 PECAM1
7 central nervous system hemangioma 32.5 VEGFA PECAM1
8 glomeruloid hemangioma 32.5 VEGFA PECAM1
9 hobnail hemangioma 32.4 PECAM1 PDPN FLT4
10 acquired hemangioma 32.3 PROX1 PECAM1 PDPN
11 capillary hemangioma 32.3 VHL VEGFA TEK SLC2A1 PROX1 PECAM1
12 hemangioma of liver 32.2 VHL KRIT1
13 liver angiosarcoma 31.9 PECAM1 KRAS
14 angiosarcoma 31.3 VEGFA TEK PROX1 PECAM1 PDPN KRAS
15 vascular cancer 31.3 VEGFA PECAM1 PDPN KDR FLT4 FGF2
16 klippel-trenaunay-weber syndrome 31.2 TEK KRIT1 FLT4
17 lymphangioma 31.1 VEGFA PROX1 PECAM1 PDPN KRAS KDR
18 intussusception 30.9 VEGFA TEK PECAM1 KDR FGF2
19 retinal vascular disease 30.9 VEGFA TEK KDR FGF2
20 sarcoma 30.8 VEGFA KRAS KDR FLT4 FGF2
21 adenocarcinoma 30.8 VEGFA PTEN NKX2-1 KRAS KDR
22 kaposiform hemangioendothelioma 30.8 PROX1 PECAM1 KDR GNA14 FLT4
23 microvascular complications of diabetes 5 30.7 VEGFA TEK KDR FGF2
24 angiokeratoma circumscriptum 30.7 VEGFA TEK SLC2A1 PECAM1 KDR
25 cystic lymphangioma 30.6 PROX1 PECAM1 PDPN
26 neurofibroma 30.6 VEGFA PTEN PDPN
27 macular degeneration, age-related, 1 30.6 VEGFA TEK PECAM1 KDR FLT4 FGF2
28 gastrointestinal stromal tumor 30.5 VEGFA TEK PTEN KRAS KDR
29 malignant astrocytoma 30.5 VEGFA PTEN NOTCH1 FGF2
30 benign mesothelioma 30.5 PECAM1 PDPN NKX2-1
31 neovascular glaucoma 30.5 VEGFA KDR FGF2
32 small cell carcinoma 30.5 PTEN NKX2-1 KRAS
33 cystic teratoma 30.5 PTEN NKX2-1 KRAS
34 hemifacial spasm 30.4 VEGFA FLT4
35 rhabdomyosarcoma 30.4 VEGFA PTEN KRAS KDR FGF2
36 hemangioblastoma 30.3 VHL VEGFA SLC2A1 PECAM1 PDPN KDR
37 juvenile nasopharyngeal angiofibroma 30.3 VEGFA PECAM1 FGF2
38 differentiated thyroid carcinoma 30.3 VEGFA NKX2-1 KRAS
39 ischemia 30.3 VEGFA TEK KDR FGF2
40 placental insufficiency 30.3 VEGFA TEK KDR FGF2
41 adenoid cystic carcinoma 30.3 VEGFA PTEN NOTCH1 KRAS
42 renal cell carcinoma, nonpapillary 30.2 VHL VEGFA TEK SLC2A1 PTEN PECAM1
43 medulloblastoma 30.2 VEGFA PTEN PECAM1 NOTCH1 KDR FGF2
44 pediatric angiosarcoma 30.2 VEGFA PECAM1
45 exudative vitreoretinopathy 1 30.2 VEGFA TEK PECAM1 KDR FGF2
46 lung cancer susceptibility 3 30.2 VEGFA PECAM1 NKX2-1 KRAS KDR FLT4
47 gorham's disease 30.2 VEGFA PECAM1 PDPN FLT4
48 myeloma, multiple 30.2 VEGFA PTEN NOTCH1 NKX2-1 KRAS FGF2
49 wilms tumor 1 30.2 VHL SLC2A1 PDPN NOTCH1 NKX2-1 KRAS
50 glomangioma 30.1 TEK PECAM1

Graphical network of the top 20 diseases related to Hemangioma:



Diseases related to Hemangioma
Sources

Symptoms & Phenotypes for Hemangioma

About this section

GenomeRNAi Phenotypes related to Hemangioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 FLT4 GNA14 KDR KRAS NOTCH1 VEGFA
2 Decreased sensitivity to paclitaxel GR00112-A-0 8.65 PTEN

MGI Mouse Phenotypes related to Hemangioma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.53 ANTXR1 FGF2 FLT4 KDR KRAS KRIT1
2 homeostasis/metabolism MP:0005376 10.47 DIPK1A FGF2 FLT4 KDR KRAS MYH9
3 growth/size/body region MP:0005378 10.46 ANTXR1 FLT4 KDR KRAS KRIT1 MYH9
4 cellular MP:0005384 10.44 ANTXR1 FGF2 KDR KRAS MYH9 NKX2-1
5 mortality/aging MP:0010768 10.41 ANTXR1 FGF2 FLT4 KDR KRAS KRIT1
6 hematopoietic system MP:0005397 10.39 DIPK1A FGF2 KDR KRAS MYH9 NOTCH1
7 embryo MP:0005380 10.35 FLT4 KDR KRAS KRIT1 MYH9 NOTCH1
8 immune system MP:0005387 10.34 ANTXR1 FLT4 KDR KRAS MYH9 NOTCH1
9 digestive/alimentary MP:0005381 10.32 FLT4 KRAS NKX2-1 NOTCH1 PDPN PECAM1
10 muscle MP:0005369 10.3 FGF2 FLT4 KDR KRAS KRIT1 NOTCH1
11 nervous system MP:0003631 10.22 FGF2 KDR KRAS KRIT1 MYH9 NKX2-1
12 integument MP:0010771 10.21 FLT4 KDR KRAS NOTCH1 PDPN PKD1
13 craniofacial MP:0005382 10.19 ANTXR1 KDR KRAS KRIT1 NOTCH1 PKD1
14 liver/biliary system MP:0005370 10.19 FLT4 KDR KRAS NOTCH1 PECAM1 PKD1
15 neoplasm MP:0002006 10.13 ANTXR1 FGF2 KRAS KRIT1 NKX2-1 NOTCH1
16 normal MP:0002873 10.1 FLT4 KDR KRAS MYH9 NKX2-1 NOTCH1
17 no phenotypic analysis MP:0003012 9.97 ANTXR1 FLT4 KDR KRAS MYH9 NKX2-1
18 renal/urinary system MP:0005367 9.86 KRAS MYH9 NOTCH1 PECAM1 PKD1 PTEN
19 respiratory system MP:0005388 9.85 KDR KRAS NKX2-1 NOTCH1 PDPN PECAM1
20 skeleton MP:0005390 9.73 ANTXR1 FGF2 KDR KRAS NKX2-1 NOTCH1
21 vision/eye MP:0005391 9.36 FGF2 KDR KRAS KRIT1 MYH9 NOTCH1
Sources

Drugs & Therapeutics for Hemangioma

About this section

Drugs for Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
2
parecoxib Approved Phase 4 198470-84-7
3
Timolol Approved Phase 4 26839-75-8 33624 5478
4
Captopril Approved Phase 4 62571-86-2 44093
5 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Maleic acid Experimental Phase 4 110-16-7 444266
8 Analgesics, Non-Narcotic Phase 4
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Antirheumatic Agents Phase 4
11 Cyclooxygenase 2 Inhibitors Phase 4
12 Cyclooxygenase Inhibitors Phase 4
13 Ophthalmic Solutions Phase 4
14 Angiotensin-Converting Enzyme Inhibitors Phase 4
15 HIV Protease Inhibitors Phase 4
16
protease inhibitors Phase 4
17 Calcineurin Inhibitors Phase 4
18
Nadolol Approved Phase 3 42200-33-9 39147
19
Atenolol Approved Phase 3 29122-68-7 2249
20
Acebutolol Approved, Investigational Phase 3 37517-30-9 1978
21 Sympatholytics Phase 3
22 Adrenergic beta-1 Receptor Antagonists Phase 3
23 Sympathomimetics Phase 3
24 Strawberry Approved Phase 2
25
Bosentan Approved, Investigational Phase 2 147536-97-8 104865
26
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
27
Propranolol Approved, Investigational Phase 2 525-66-6 4946
28
tannic acid Approved Phase 2 1401-55-4
29
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
30
Lovastatin Approved, Investigational Phase 2 75330-75-5 53232
31 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
32
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
34
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
35
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
36
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
37
Imiquimod Approved, Investigational Phase 2 99011-02-6 57469
38
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
39
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
40 Endothelin Receptor Antagonists Phase 2
41 Adrenergic Antagonists Phase 2
42 Adrenergic beta-Antagonists Phase 2
43 Antihypertensive Agents Phase 2
44 Neurotransmitter Agents Phase 2
45 Adrenergic Agents Phase 2
46 Anti-Arrhythmia Agents Phase 2
47 Vasodilator Agents Phase 2
48 Lipid Regulating Agents Phase 2
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
50 Hypolipidemic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 A Randomized, Phase IV Study Exploring the Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4 Parecoxib Sodium
2 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Completed NCT01908972 Phase 4 Prednisolone;Propranolol
3 A Pilot Study of Hemoporfin Photodynamic Therapy in Children (7-14 Years Old) With Port-wine Stain Completed NCT03125057 Phase 4 Hemoporfin PDT
4 Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma Recruiting NCT04288700 Phase 4 oral propranolol;Oral Captopril;intralesional propranolol injection;topical Timolol maleate 0.5% eye drops
5 Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
6 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
7 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
8 A Pilot Study of Hemoporfin Photodynamic Therapy in Children (2-7 Years Old) With Port-wine Stain Recruiting NCT04106258 Phase 4 Hemoporfin PDT
9 Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Recruiting NCT03181984 Phase 4 Hemoporfin
10 Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Unknown status NCT03237637 Phase 3 oral propranolol;oral atenolol
11 Treatment of Cutaneous Hemangioma of Infancy With Topical 0.5% Timolol Maleate Eye Drop Compared With Placebo in Pediatric Patients, Siriraj Hospital Unknown status NCT01685398 Phase 3 0.5% timolol maleate eye drop;Normal saline
12 Blood Oxygen Level Dependent fMRI Navigation for Function Protection in Intracranial Arteriovenous Malformation Surgery: a Multicenter Prospective Randomized Controlled Single Blind Clinical Trial Unknown status NCT01758211 Phase 3
13 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
14 Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial Completed NCT02505971 Phase 3 Nadolol;Propranolol
15 A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind). Completed NCT01056341 Phase 2, Phase 3 Propranolol;Placebo
16 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Completed NCT02342275 Phase 3 Propranolol;Atenolol
17 The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial Completed NCT00312520 Phase 3 prednisolone;methylprednisolone
18 A Randomized Trial of Unruptured Brain Arteriovenous Malformations Completed NCT00389181 Phase 3
19 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation Completed NCT01677624 Phase 3
20 CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial. Recruiting NCT02332408 Phase 3
21 Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas Terminated NCT00744185 Phase 2, Phase 3 propranolol treatment;placebo treatment
22 Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Terminated NCT01743885 Phase 3 Acebutolol;Propanolol
23 Topical Timolol Gel for the Treatment of Infantile Hemangiomas Completed NCT02145884 Phase 2 timolol maleate 0.5% gel
24 A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy Completed NCT00601016 Phase 2 Imiquimod 5% cream
25 Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control Completed NCT01010308 Phase 2 Nadolol
26 Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial Completed NCT02731287 Phase 2 Timolol;Placebo
27 A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma Completed NCT01072045 Phase 2 Propranolol;Prednisone
28 A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo. Completed NCT01512173 Phase 2 propranolol gel;Placebo
29 Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH) Completed NCT02913612 Phase 2 0.25% Timolol Maleate Gel Forming Solution;0.5% Timolol Maleate Gel Forming Solution
30 Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Completed NCT00389935 Phase 2 Thalidomide
31 U.S. Multicenter, Randomized Controlled Study Comparing the Performance fo Onyx(EVOH) and TRUFILL® (n-BCA)in Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs) Completed NCT00857662 Phase 2
32 Phase II Clinical Trial is to Compare Epidermal Temperature Measurements During 1.Laser Treatment at Standard Treatment Energies 2.Cryogen Spray Cooling (CSC) Plus Laser Treatment. 3.Contact Cooling Plus Laser Treatment. Completed NCT00540917 Phase 2
33 Treatment of Port-wine Stains by Bosentan in Addition to Pulsed Dye Laser (PDL) in Children or Young Adults Who Previously Failed to Respond to PDL Alone: a Monocentric Pilot Study Completed NCT02317679 Phase 2 Bosentan
34 Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma Recruiting NCT03633747 Phase 1, Phase 2 Propranolol Hydrochloride
35 Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Recruiting NCT02603328 Phase 1, Phase 2 Atorvastatin
36 Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations Recruiting NCT02042326 Phase 2 Sirolimus
37 Treat_CCM Clinical Trial A Multicenter Randomized Clinical Trial on Propranolol in Cerebral Cavernous Malformation Recruiting NCT03589014 Phase 2 Propranolol
38 A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE). Active, not recruiting NCT02110069 Phase 2 Vincristine;Sirolimus
39 Effect of Oral Propranolol on mRNA Expression in Symptomatice Caavernous Malformation Active, not recruiting NCT03474614 Phase 2 Propranolol
40 '' Efficacy of Propranolol in the Treatment of Infantile Hemangioma" Not yet recruiting NCT04684667 Phase 2 Propranolol Therapy for Infantile Hemangioma
41 Lovastatin for Treatment of Brain Arteriovenous Malformations:a Double-blind, Placebo-controlled Randomized Trial Not yet recruiting NCT04297033 Phase 2 Lovastatin;Placebo
42 Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study Terminated NCT00967226 Phase 2 propranolol;Prednisolone
43 A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH) Terminated NCT01074437 Phase 2 Prednisolone (Corticosteroid);Propranolol;Placebo
44 A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile Terminated NCT00555464 Phase 2 Vincristine;Prednisone
45 The Effects of Aldara as an Adjunct to Laser Treatment of Port Wine Stains Terminated NCT00979550 Phase 2 Imiquimod;non-medicated petroleum cream
46 The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas Withdrawn NCT01408056 Phase 2 Timolol 0.5% Gel Forming Solution (GFS);Mupirocin 2% Ointment
47 Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks Withdrawn NCT00969397 Phase 1, Phase 2 Topical Antiangiogenic
48 Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes Metastasis Unknown status NCT02496013 Phase 1 68Ga-NEB
49 Oral Propanolol for Surgically Inaccessible Cerebral and Spinal Cavernous Malformations Unknown status NCT03523650 Phase 1 Propranolol Oral Tablet;Placebo Oral Tablet
50 Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin Completed NCT03649113 Phase 1

Search NIH Clinical Center for Hemangioma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: hemangioma

Sources

Genetic Tests for Hemangioma

About this section

Genetic tests related to Hemangioma:

# Genetic test Affiliating Genes
1 Hemangioma 29
Sources

Anatomical Context for Hemangioma

About this section

MalaCards organs/tissues related to Hemangioma:

40
Endothelial, Skin, Liver, Breast, Spleen, Spinal Cord, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hemangioma:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Cardinal Veins Venous Endothelial Cells Affected by disease
Sources

Publications for Hemangioma

About this section

Articles related to Hemangioma:

(show top 50) (show all 18614)
# Title Authors PMID Year
1
[Sinusoidal hemangioma: Immunohistochemical analysis with glucose transporter 1 (GLUT1) and williams tumor protein 1 (WT1)]. 54 61
20487697 2010
2
Differential expression of VEGF121, VEGF165 and VEGF189 in angiomas and squamous cell carcinoma cell lines of the head and neck. 61 54
20393000 2010
3
Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. 61 54
20237346 2010
4
Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. 54 61
20015661 2010
5
Facial nerve hemangiomas: vascular tumors or malformations? 54 61
20096233 2010
6
[Distribution, GLUT-1 expression and early surgical intervention for infantile hemangioma on the face]. 54 61
20030103 2009
7
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. 61 54
19620773 2009
8
Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report. 61 54
19689513 2009
9
Treatment of hemangioma by transfection of antisense VEGF gene. 61 54
19513617 2009
10
[POEMS syndrome with an isolated lytic lesion and glomeruloid hemangiomas: report of one case]. 54 61
19701559 2009
11
Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. 54 61
19349369 2009
12
[Expression and significance of basic fibroblast growth factor in infant vascular anomalies]. 61 54
19417990 2009
13
A potential role for notch signaling in the pathogenesis and regulation of hemangiomas. 61 54
19169152 2009
14
Suppressing NFAT increases VEGF signaling in hemangiomas. 61 54
19061833 2008
15
Solitary pulmonary infantile hemangioma in an infant with atrial septal defect. 61 54
17990917 2008
16
Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. 54 61
18814928 2008
17
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. 61 54
18931684 2008
18
GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. 54 61
18620729 2008
19
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. 61 54
18671617 2008
20
Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation. 54 61
18434035 2008
21
[Current treatment of infantile hemangiomas: an overview of the literature]. 54 61
18784870 2008
22
Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. 54 61
18535669 2008
23
Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. 54 61
18261103 2008
24
Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. 54 61
18084256 2008
25
Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9. 54 61
17888584 2008
26
Lack of expression of podoplanin by microvenular hemangioma. 61 54
18650031 2008
27
Eccrine angiomatous hamartoma with features resembling verrucous hemangioma. 54 61
17997743 2007
28
[Expression and significance of Ang1, Ang2 and receptor Tie2 in hemangioma]. 61 54
18269030 2007
29
Effect of anti-KDR antibody on the proliferation of hemangioma vascular endothelial cells in vitro. 54 61
18060633 2007
30
[Head and neck hemangiomas: how and when to treat]. 61 54
17924011 2007
31
Placental anomalies in children with infantile hemangioma. 61 54
17845154 2007
32
[Differential expression of CD133, Glut-1 in tissues and endothelial cells derived from infantile hemangioma and vascular malformation]. 61 54
17926859 2007
33
[Iodothyronine deiodinases expression in thyroid neoplasias]. 54 61
17891232 2007
34
[The expression and role of glucose transporter-1 in infantile hemangioma]. 54 61
17554865 2007
35
GLUT-1 in oral benign vascular lesions. 54 61
17241430 2007
36
[Expression of PCNA, VEGF and bFGF in endothelial cells of juvenile nasopharyngeal angiofibroma]. 61 54
17285972 2006
37
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. 61 54
16741507 2006
38
Hemangiomas and homeobox gene expression. 54 61
16877932 2006
39
[Delayed disappearance of h-VEGF₁₆₅ mRNA and protein under regulation of hypoxic response element]. 61 54
16786114 2006
40
Vascular complications in Chuvash polycythemia. 54 61
16673284 2006
41
Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. 61 54
16424896 2006
42
[Role of urinary basic fibroblast growth factor in differentiating hemangiomas from vascular malformation]. 61 54
16635349 2006
43
The potential efficacy of omega-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy. 54 61
16500033 2006
44
Transforming growth factor-beta promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. 54 61
16037131 2005
45
Unique association of non-functioning pheochromocytoma, ganglioneuroma, adrenal cortical adenoma, hepatic and vertebral hemangiomas in a patient with a new intronic variant in the VHL gene. 54 61
16483185 2005
46
Transgenic rabbits with increased VEGF expression develop hemangiomas in the liver: a new model for Kasabach-Merritt syndrome. 61 54
16200077 2005
47
Hemangiomas of infancy: clinical and biological characteristics. 61 54
16327961 2005
48
Assessment of angiogenic markers in oral hemangiomas and pyogenic granulomas. 61 54
16005715 2005
49
Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. 61 54
15988268 2005
50
Expression patterns of markers for type II pneumocytes in pulmonary sclerosing hemangiomas and fetal lung tissues. 54 61
15974816 2005
Sources

Variations for Hemangioma

About this section

ClinVar genetic disease variations for Hemangioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN):c.675T>G (p.Tyr225Ter) SNV Pathogenic 404162 rs1057520900 10:89717650-89717650 10:87957893-87957893
2 DIPK1A NM_000969.5(RPL5):c.74-1G>C SNV Pathogenic 523383 rs1553284997 1:93299101-93299101 1:92833544-92833544
3 PKD1 NM_001009944.3(PKD1):c.359T>C (p.Ile120Thr) SNV Likely pathogenic 523386 rs1555459345 16:2169115-2169115 16:2119114-2119114
4 ARG2 GRCh37/hg19 14q24.1(chr14:68126321-68269053)x3 copy number gain Uncertain significance 635772 14:68110557-68283783
5 NOTCH1 NM_017617.5(NOTCH1):c.5674G>A (p.Gly1892Arg) SNV Uncertain significance 983426 9:139395264-139395264 9:136500812-136500812
6 SRD5A3-AS1 NM_024592.5(SRD5A3):c.951_955del (p.Phe318fs) Deletion Uncertain significance 632442 rs565935886 4:56236248-56236252 4:55370081-55370085
7 CSMD3 GRCh37/hg19 8q23.3(chr8:114378494-114450308) copy number loss Benign 523292 8:114378494-114450308
Sources

Expression for Hemangioma

About this section
Search GEO for disease gene expression data for Hemangioma.
Sources

Pathways for Hemangioma

About this section

Pathways related to Hemangioma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.72 VHL VEGFA TEK PTEN NOTCH1 MYH9
2
Akt Signaling 63
Show member pathways
 13.36 TEK PTEN KRAS KDR GNA14 FLT4
3
CREB Pathway 63
Show member pathways
 13.27 TEK PTEN KRAS KDR GNA14 FLT4
4
PAK Pathway 63
Show member pathways
 13.2 TEK SLC2A1 PTEN NOTCH1 MYH9 KRAS
5
Phospholipase-C Pathway 63
Show member pathways
 13.01 PTEN KRAS KDR GNA14 FLT4 FGF2
6
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.9 TEK MYH9 KDR GNA14 FLT4
7
PI3K-Akt signaling pathway 36
Show member pathways
 12.84 VEGFA TEK PTEN NOTCH1 KRAS KDR
8
Gastric cancer 36
Show member pathways
 12.72 PTEN NOTCH1 KRAS FLT4 FGF2
9
MAPK signaling pathway 36 1
12.71 VEGFA TEK KRAS KDR FLT4 FGF2
10
Ras signaling pathway 36
Show member pathways
 12.62 VEGFA TEK KRIT1 KRAS KDR FLT4
11
Pathways in cancer 36
12.48 VHL VEGFA SLC2A1 PTEN NOTCH1 KRAS
12
VEGF Signaling 66
Show member pathways
 12.45 VEGFA PTEN KRAS KDR FGF2
13
ErbB signaling pathway 36 1
Show member pathways
 12.42 VHL VEGFA SLC2A1 PTEN KRAS KDR
14
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.35 TEK KRAS KDR FLT4 FGF2
15
RhoGDI Pathway 63
Show member pathways
 12.35 VEGFA MYH9 KDR FLT4 FGF2
16
Calcium signaling pathway 36
12.34 VEGFA KDR GNA14 FLT4 FGF2
17
Proteoglycans in cancer 36
12.25 VEGFA KRAS KDR FGF2
18
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.18 TEK PTEN KRAS KDR FLT4
19
Tyrosine Kinases / Adaptors 4
12.08 TEK KDR FLT4 FGF2
20
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.98 VEGFA PROX1 NOTCH1 KDR FGF2
21
HIF-1 signaling pathway 36
11.92 VHL VEGFA TEK SLC2A1
22
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.81 VHL VEGFA KDR FLT4
23
VEGF Pathway (Tocris) 60
Show member pathways
 11.76 KRAS KDR FLT4
24
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.74 VEGFA SLC2A1 NOTCH1 FGF2
25
Central carbon metabolism in cancer 36
11.67 SLC2A1 PTEN KRAS
26
HIF1Alpha Pathway 63
11.54 VHL VEGFA SLC2A1
27
Cardiac Progenitor Differentiation 1
11.53 NOTCH1 KDR FGF2
28
Cell adhesion_Plasmin signaling 23
11.49 VEGFA KDR FGF2
29
Differentiation Pathway 1
11.47 VEGFA NOTCH1 FGF2
30
Integrins in angiogenesis 1
11.45 VEGFA KDR FGF2
31
HIF-2-alpha transcription factor network 1
11.2 VHL VEGFA SLC2A1 KDR
32
Angiogenesis (CST) 4
11.17 TEK PROX1 PECAM1 PDPN NOTCH1 KDR
33
Vemurafenib Pathway, Pharmacodynamics 60
10.99 VEGFA KRAS KDR FLT4 FGF2
34
G-protein signaling_Rap2B regulation pathway 23
10.97 TEK KDR GNA14 FLT4 FGF2
35
Angiogenesis (WikiPathways) 1
10.94 VEGFA TEK KDR FGF2
36
Amplification and Expansion of Oncogenic Pathways as Metastatic Traits 1
10.93 VHL VEGFA NOTCH1
37
VEGF binds to VEGFR leading to receptor dimerization 65
Show member pathways
 10.87 VEGFA KDR FLT4
Sources

GO Terms for Hemangioma

About this section

Cellular components related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.13 VHL VEGFA TEK SLC2A1 PTEN PROX1
2 integral component of plasma membrane GO:0005887 9.98 TEK SLC2A1 PKD1 PECAM1 PDPN KDR
3 plasma membrane GO:0005886 9.8 TEK SLC2A1 PTEN PKD1 PECAM1 PDPN
4 basolateral plasma membrane GO:0016323 9.71 TEK SLC2A1 PKD1 PDPN
5 receptor complex GO:0043235 9.67 TEK NOTCH1 KDR FLT4
6 cell-cell junction GO:0005911 9.62 TEK SLC2A1 PECAM1 KRIT1
7 apical plasma membrane GO:0016324 9.55 TEK SLC2A1 PTEN PDPN NOTCH1
8 membrane raft GO:0045121 9.1 TEK SLC2A1 PECAM1 PDPN KRAS KDR

Biological processes related to Hemangioma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.18 VEGFA TEK PROX1 PDPN NOTCH1 KDR
2 negative regulation of cell proliferation GO:0008285 10.09 VHL PTEN PROX1 PDPN NOTCH1
3 positive regulation of gene expression GO:0010628 10.08 VEGFA PTEN NOTCH1 NKX2-1 KRAS FGF2
4 negative regulation of gene expression GO:0010629 10.04 VHL VEGFA NOTCH1 KDR FGF2
5 negative regulation of apoptotic process GO:0043066 10.04 VHL VEGFA TEK PTEN PDPN KDR
6 heart development GO:0007507 10.01 TEK PTEN PKD1 NOTCH1
7 positive regulation of cell proliferation GO:0008284 10.01 VEGFA PTEN PROX1 NOTCH1 KRAS KDR
8 in utero embryonic development GO:0001701 10 VEGFA PKD1 NOTCH1 MYH9
9 positive regulation of cell migration GO:0030335 10 VEGFA PECAM1 PDPN NOTCH1 KDR
10 cell-cell adhesion GO:0098609 9.97 PKD1 PECAM1 PDPN MYH9
11 positive regulation of angiogenesis GO:0045766 9.96 VEGFA TEK KDR FGF2
12 regulation of cell shape GO:0008360 9.95 VEGFA PDPN MYH9 KDR
13 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 VEGFA TEK PTEN NOTCH1 KDR FLT4
14 positive regulation of MAPK cascade GO:0043410 9.88 VEGFA TEK KDR FLT4 FGF2
15 positive regulation of kinase activity GO:0033674 9.87 TEK KDR FLT4
16 positive regulation of protein phosphorylation GO:0001934 9.87 VEGFA TEK PECAM1 KRAS KDR FLT4
17 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.86 VEGFA KDR FLT4
18 positive regulation of epithelial cell proliferation GO:0050679 9.86 VEGFA NOTCH1 FGF2
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.86 VEGFA TEK KDR FGF2
20 positive regulation of MAP kinase activity GO:0043406 9.85 VEGFA KRAS FGF2
21 liver development GO:0001889 9.85 PROX1 PKD1 NOTCH1 KRAS
22 positive regulation of blood vessel endothelial cell migration GO:0043536 9.84 VEGFA KDR FGF2
23 neural tube development GO:0021915 9.83 PROX1 PKD1 NOTCH1
24 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 TEK KRIT1 KDR
25 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.8 VEGFA KDR FGF2
26 branching morphogenesis of an epithelial tube GO:0048754 9.77 VEGFA PKD1 NOTCH1
27 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.76 VEGFA NOTCH1 KDR FLT4
28 positive regulation of focal adhesion assembly GO:0051894 9.74 VEGFA TEK KDR
29 sprouting angiogenesis GO:0002040 9.73 VEGFA TEK NOTCH1 FLT4
30 lung development GO:0030324 9.73 VEGFA PROX1 PDPN NOTCH1 NKX2-1 FGF2
31 endothelial cell differentiation GO:0045446 9.72 PROX1 KDR
32 regulation of synaptic transmission, GABAergic GO:0032228 9.72 PTEN KRAS
33 dentate gyrus development GO:0021542 9.72 PTEN PROX1
34 positive regulation of positive chemotaxis GO:0050927 9.71 VEGFA KDR
35 lymph vessel development GO:0001945 9.71 PROX1 FLT4
36 tube formation GO:0035148 9.71 VEGFA NOTCH1
37 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.71 VEGFA NOTCH1
38 cell migration involved in sprouting angiogenesis GO:0002042 9.71 VEGFA KDR FGF2
39 positive regulation of protein kinase C signaling GO:0090037 9.7 VEGFA FLT4
40 positive regulation of cellular component movement GO:0051272 9.7 VEGFA PDPN
41 vascular endothelial growth factor signaling pathway GO:0038084 9.7 VEGFA KDR FLT4
42 vascular wound healing GO:0061042 9.69 VEGFA KDR
43 coronary artery morphogenesis GO:0060982 9.69 VEGFA NOTCH1
44 lymphangiogenesis GO:0001946 9.69 PROX1 PDPN FLT4
45 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.68 VEGFA NOTCH1
46 venous blood vessel morphogenesis GO:0048845 9.67 PROX1 NOTCH1
47 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.66 VEGFA KDR
48 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.66 VEGFA KDR
49 positive regulation of epithelial tube formation GO:1905278 9.64 VEGFA FGF2
50 positive regulation of endothelial cell proliferation GO:0001938 9.63 VEGFA TEK PROX1 KDR FLT4 FGF2

Molecular functions related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 VHL VEGFA TEK SLC2A1 PTEN PROX1
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 TEK KDR FLT4
3 chemokine binding GO:0019956 9.37 PDPN FGF2
4 growth factor binding GO:0019838 9.33 TEK KDR FLT4
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.32 KDR FLT4
6 identical protein binding GO:0042802 9.28 VEGFA TEK SLC2A1 PTEN NOTCH1 MYH9
Sources

Sources for Hemangioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....